SCHEMBL3211927

SCHEMBL3211927

Fc1[c]cccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 1/20 0.48
HTR1A P08908 4/20 0.47
DRD2 P14416 1/20 0.47
LIPE Q05469 1/20 0.46
LTA4H P09960 1/20 0.45
MAPK14 Q16539 1/20 0.45
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
GAA P10253 1/20 0.44
ALPG P10696 1/20 0.44
PTK2B Q14289 1/20 0.44
KDM1A O60341 3/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
CCNB2 O95067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL920470 0.89 ALDH1A1 (0.50) MAPTNPC1HTR1ASLC6A2SLC6A4
SCHEMBL8079401 0.87 PTGER1 (0.49) MAPTL3MBTL1MAPK1TDP1NPC1
SCHEMBL920040 0.85 KMT2A (0.44) MAPTL3MBTL1MAPK1TDP1NPC1
SCHEMBL921724 0.85 SMN1; SMN2 (0.50) MAPTNPC1LTA4HMAPK14ALDH1A1
SCHEMBL921988 0.85 MAPT (0.46) MAPTL3MBTL1NPC1HTR1AMAPK14
SCHEMBL921216 0.83 IDO1 (0.51) MAPTL3MBTL1GAAALDH1A1LMNA
SCHEMBL921474 0.83 CYP11B1 (0.49) NPC1HTR1ADRD2
SCHEMBL919103 0.83 DHFR (0.45) MAPTL3MBTL1NPC1HTR1ASLC6A2
SCHEMBL919788 0.82 NPC1 (0.51) NPC1HTR1AADRA1DADRA1AADRA1B
SCHEMBL921411 0.81 IDO1 (0.44) DRD2MAPK14LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013049701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2013-04-04 WO disclosed
EP-1957496-B1 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2012-10-24 EP disclosed
CN-1898240-B Imidazopyrazine tyrosine kinase inhibitors OSI PHARM INC 2011-08-03 CN disclosed
US-20100041694-A1 AGRICULTURAL COMPOSITION FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENIC MICROBES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-18 US disclosed
CN-101641012-A Agricultural composition for controlling or preventing plant diseases caused by plant pathogenic microbes SUMITOMO CHEMICAL CO JP 2010-02-03 CN disclosed
US-7648987-B2 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-19 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 EP disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
EP-1957496-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-08-20 EP disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 US disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 WO disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 US disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed
EP-1675860-A2 IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-07-05 EP disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed
WO-2005037836-A2 IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041694-A1 AGRICULTURAL COMPOSITION FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENIC MICROBES HDHD5, NAAA, BROX MAPT 388/4885L3MBTL1 1891/4885MAPK1 2539/4885
US-20070149521-A1 Bicyclic protein kinase inhibitors CDK1, MAP4K2, MAP4K3 MAPT 1073/4885L3MBTL1 3960/4885MAPK1 18/4885
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 MAPT 2935/4885L3MBTL1 3074/4885MAPK1 106/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 MAPT 2935/4885L3MBTL1 3074/4885MAPK1 106/4885
US-20070208053-A1 Fused heterobicyclic kinase inhibitors MAP2K5, MAP2K7, MAP2K2 MAPT 3449/4885L3MBTL1 3482/4885MAPK1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.